# Amygdala Neurosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amygdala-neurosciences

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.amygns.com
- Total disclosed funding: $2M
- Latest round: Seed (Jun 8, 2017)
- Investors on record: 1

## About

Based in California, US, and founded in 2015 by CEO Brent Blackburn, Ivan Diamond, and Lou Lange, Amygdala Neurosciences, Inc., a.k.a. Amygdala Neurosciences operates as a biopharmaceutical company that focuses on the development and commercializing of therapies for addiction disorders. In May 2024, Amygdala Neurosciences, Inc. raised venture funding led by the Alcohol Beverage Medicines Research Foundation (ABMRF).

Amygdala Neurosciences is developing ANS-858, a selective, reversible inhibitor of the enzyme ALDH2, currently in preclinical development. ANS-858 is used to reduce the self-administration of addictive substances such as alcohol, nicotine, cocaine, and opiates. ANS-858 is designed to address alcohol use disorder primarily, with potential applications for smoking cessation and opioid and stimulant use disorders.

The company plans to use its proceeds from May 2024 funding for the development of the ANS-858 drug.

## Funding rounds

- Seed, Jun 8, 2017, $2M — Asset Management Ventures

## Investors

- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Seed